You are here

Spark Therapeutics

JPM19: Spark looks at scale, manufacturing as gene therapy matures

JPM19: Spark looks at scale, manufacturing as gene therapy matures

Biopharma Dive

Spark Therapeutics

Flag link:

2 Sets of Disasters Biotech Will Pay For in 2019

2 Sets of Disasters Biotech Will Pay For in 2019

Yahoo/Motley Fool

Gilead Sciences

Spark Therapeutics

Flag link:

Luxturna cleared for sale in Europe, but payer support uncertain

Luxturna cleared for sale in Europe, but payer support uncertain

Biopharma Dive

Spark Therapeutics

Flag link:

Novartis/Spark’s sight gene therapy approved in EU

Novartis/Spark’s sight gene therapy approved in EU

Pharmaforum

Spark Therapeutics

Flag link:

Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth

Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth

Endpoints

Spark Therapeutics

Flag link:

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark/Novartis eye gene therapy nears EU market – but at what price?

Pharmaforum

Spark Therapeutics

Flag link:

Express Scripts staking out million-dollar gene therapies

Express Scripts staking out million-dollar gene therapies

Reuters

Express Scripts

Spark Therapeutics

Flag link:

What's Next for Spark Therapeutics

What's Next for Spark Therapeutics

Motley Fool

Spark Therapeutics

Flag link:

3 Beaten-Down Biotech Stocks: Can They Recover?

3 Beaten-Down Biotech Stocks: Can They Recover?

Motley Fool

Spark Therapeutics

Flag link:

7 companies to watch during Q2 earnings

7 companies to watch during Q2 earnings

Biopharma Dive

Gilead Sciences

Spark Therapeutics

Flag link:

3 Biotech Stocks With Major Catalysts Incoming

3 Biotech Stocks With Major Catalysts Incoming

Motley Fool

Spark Therapeutics

Progenics Pharmaceuticals

Flag link:

Is biopharma’s first $1.5M therapy now in Phase III?

Is biopharma’s first $1.5M therapy now in Phase III?

Endpoints

Spark Therapeutics

Flag link:

Sparks sells regulatory fast pass to Jazz for $110M

Sparks sells regulatory fast pass to Jazz for $110M

Biopharma Dive

Spark Therapeutics

Jazz Pharmaceuticals

priority review vouchers

Flag link:

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

Stat

Spark Therapeutics

Flag link:

Spark lays groundwork for US Luxturna launch

Spark lays groundwork for US Luxturna launch

Biopharma Dive

Spark Therapeutics

Flag link:

Cost over sight? Spark's blindness cure has the industry talking

Cost over sight? Spark's blindness cure has the industry talking

Medical Marketing and Media

Spark Therapeutics

Flag link:

Novartis move signals further gene therapy resurgence

Novartis move signals further gene therapy resurgence

EP Vantage

Spark Therapeutics

Flag link:

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Yahoo/Reuters

Spark Therapeutics

Flag link:

Three Interviews From the J.P. Morgan Healthcare Conference

Three Interviews From the J.P. Morgan Healthcare Conference

Motley Fool

Arena Pharmaceuticals

Spark Therapeutics

Flag link:

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Reuters

Spark Therapeutics

Flag link:

Pages